Top

Journal of Endocrinological Investigation

Published in:

Open Access 28-06-2023 | Obesity | Review

Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?

Authors: V. A. Genchi, G. Palma, G. P. Sorice, R. D’Oria, C. Caccioppoli, N. Marrano, G. Biondi, I. Caruso, A. Cignarelli, A. Natalicchio, L. Laviola, F. Giorgino, S. Perrini

Published in: Journal of Endocrinological Investigation | Issue 11/2023

Abstract

Background

Adaptive thermogenesis represents the main mechanism through which the body generates heat in response to external stimuli, a phenomenon that includes shivering and non-shivering thermogenesis. The non-shivering thermogenesis is mainly exploited by adipose tissue characterized by a brown aspect, which specializes in energy dissipation. A decreased amount of brown adipose tissue has been observed in ageing and chronic illnesses such as obesity, a worldwide health problem characterized by dysfunctional adipose tissue expansion and associated cardiometabolic complications. In the last decades, the discovery of a trans-differentiation mechanism (“browning”) within white adipose tissue depots, leading to the generation of brown-like cells, allowed to explore new natural and synthetic compounds able to favour this process and thus enhance thermogenesis with the aim of counteracting obesity. Based on recent findings, brown adipose tissue-activating agents could represent another option in addition to appetite inhibitors and inhibitors of nutrient absorption for obesity treatment.

Purpose

This review investigates the main molecules involved in the physiological (e.g. incretin hormones) and pharmacological (e.g. β3-adrenergic receptors agonists, thyroid receptor agonists, farnesoid X receptor agonists, glucagon-like peptide-1, and glucagon receptor agonists) modulation of adaptive thermogenesis and the signalling mechanisms involved.

Plourde G (2002) Impact of obesity on glucose and lipid profiles in adolescents atdifferentage groups in relation to adulthood. BMC Fam Pract 3:1–14. https://doi.org/10.1186/1471-2296-3-18CrossRef

Biondi G, Marrano N, Borrelli A et al (2022) Adipose tissue secretion pattern influences β cell wellness in the transition from obesity to type 2 diabetes. Int J Mol Sci 23(10):5522. https://doi.org/10.3390/IJMS23105522CrossRefPubMedPubMedCentral

Perrini S, Cignarelli A, Quaranta VN et al (2017) Correction of intermittent hypoxia reduces inflammation in obese subjects with obstructive sleep apnea JCI. Insight 2(17):e94379. https://doi.org/10.1172/JCI.INSIGHT.94379CrossRef

Genchi VA, Rossi E, Lauriola C et al (2022) Adipose tissue dysfunction and obesity-related male hypogonadism. Int J Mol Sci 23(15):8194. https://doi.org/10.3390/IJMS23158194CrossRefPubMedPubMedCentral

Palma G, Sorice GP, Genchi VA et al (2022) Adipose tissue inflammation and pulmonary dysfunction in obesity. Int J Mol Sci 23(13):7349. https://doi.org/10.3390/IJMS23137349CrossRefPubMedPubMedCentral

Ouellet V, Routhier-Labadie A, Bellemare W et al (2011) Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of ¹⁸ F-FDG-detected BAT in humans. J Clin Endocrinol Metab 96:192–199. https://doi.org/10.1210/jc.2010-0989CrossRefPubMed

Ikeda K, Maretich P, Kajimura S (2018) The common and distinct features of brown and beige adipocytes. Trends Endocrinol Metab 29:191–200. https://doi.org/10.1016/j.tem.2018.01.001CrossRefPubMedPubMedCentral

Chondronikola M, Volpi E, Børsheim E et al (2014) Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans. Diabetes 63:4089–4099. https://doi.org/10.2337/db14-0746CrossRefPubMedPubMedCentral

Chondronikola M, Volpi E, Børsheim E et al (2016) Brown adipose tissue activation is linked to distinct systemic effects on lipid metabolism in humans. Cell Metab 23:1200–1206. https://doi.org/10.1016/j.cmet.2016.04.029CrossRefPubMedPubMedCentral

10.

Wilson S, Thurlby PL, Arch JRS (1987) Substrate supply for thermogenesis induced by the β-adrenoceptor agonist BRL 26830A. Can J Physiol Pharmacol 65:113–119. https://doi.org/10.1139/y87-023CrossRefPubMed

11.

O’Mara AE, Johnson JW, Linderman JD et al (2020) Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity. J Clin Invest 130:2209–2219. https://doi.org/10.1172/JCI131126CrossRefPubMedPubMedCentral

12.

Cypess AM, Lehman S, Williams G et al (2009) Identification and importance of brown adipose tissue in adult humans. N Engl J Med 360:1509–1517. https://doi.org/10.1056/NEJMoa0810780CrossRefPubMedPubMedCentral

13.

van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM et al (2009) Cold-activated brown adipose tissue in healthy men. N Engl J Med 360:1500–1508. https://doi.org/10.1056/NEJMoa0808718CrossRefPubMed

14.

Cinti S (2002) Adipocyte differentiation and transdifferentiation: plasticity of the adipose organ. J Endocrinol Invest 25:823–835. https://doi.org/10.1007/BF03344046CrossRefPubMed

15.

Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84:277–359. https://doi.org/10.1152/physrev.00015.2003CrossRefPubMed

16.

Ishibashi J, Seale P (2010) Beige can be slimming. Science 328:1113–1114. https://doi.org/10.1126/science.1190816CrossRefPubMedPubMedCentral

17.

Min SY, Kady J, Nam M et al (2016) Human “brite/beige” adipocytes develop from capillary networks, and their implantation improves metabolic homeostasis in mice. Nat Med 22:312–318. https://doi.org/10.1038/nm.4031CrossRefPubMedPubMedCentral

18.

Cypess AM (2022) Reassessing human adipose tissue. N Engl J Med 386:768–779. https://doi.org/10.1056/NEJMRA2032804CrossRefPubMed

19.

Grilo CM, Lydecker JA, Fineberg SK et al (2022) Naltrexone-bupropion and behavior therapy, alone and combined, for binge-eating disorder: randomized double-blind placebo-controlled trial. Am J Psychiatry 179(12):927–937. https://doi.org/10.1176/appi.ajp20220267CrossRefPubMed

20.

Melia AT, Koss-Twardy SG, Zhi J (1996) The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 36:647–653. https://doi.org/10.1002/J.1552-4604.1996.TB04230.XCrossRefPubMed

21.

Billes SK, Cowley MA (2007) Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. Neuropsychopharmacology 33:1287–1297. https://doi.org/10.1038/sj.npp.1301526CrossRefPubMed

22.

Vettor R, Macor C, Rossi E et al (1994) Effect of naltrexone treatment on insulin secretion, insulin action and postprandial thermogenesis in obesity. Horm Metab Res 26:188–194. https://doi.org/10.1055/S-2007-1000809CrossRefPubMed

23.

Tremblay A, Chaput JP, Bérubé-Parent S et al (2007) The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol 63:123–134. https://doi.org/10.1007/S00228-006-0220-1CrossRefPubMed

24.

Karhunen L, Franssila-Kallunki A, Rissanen P et al (2000) Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Relat Metab Disord 24:1567–1572. https://doi.org/10.1038/SJ.IJO.0801443CrossRefPubMed

25.

Tremblay A, Royer MM, Chaput JP, Doucet É (2013) Adaptive thermogenesis can make a difference in the ability of obese individuals to lose body weight. Int J Obes (Lond) 37:759–764. https://doi.org/10.1038/IJO.2012.124CrossRefPubMed

26.

Tremblay A, Chaput JP (2009) Adaptive reduction in thermogenesis and resistance to lose fat in obese men. Brit J Nutr 102:488–492. https://doi.org/10.1017/S0007114508207245CrossRefPubMed

27.

Muzik O, Mangner TJ, Leonard WR et al (2017) Sympathetic innervation of cold-activated brown and white fat in lean young adults. J Nucl Med 58:799–806. https://doi.org/10.2967/jnumed.116.180992CrossRefPubMedPubMedCentral

28.

Paulo E, Wu D, Wang Y et al (2018) Sympathetic inputs regulate adaptive thermogenesis in brown adipose tissue through cAMP-Salt inducible kinase axis. Sci Rep 8:1–14. https://doi.org/10.1038/s41598-018-29333-6CrossRef

29.

Lockie SH, Heppner KM, Chaudhary N et al (2012) Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 61:2753–2762. https://doi.org/10.2337/db11-1556CrossRefPubMedPubMedCentral

30.

Beiroa D, Imbernon M, Gallego R et al (2014) GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes 63:3346–3358. https://doi.org/10.2337/db14-0302CrossRefPubMed

31.

Townsend LK, Medak KD, Knuth CM et al (2019) Loss of glucagon signaling alters white adipose tissue browning. FASEB J 33:4824–4835. https://doi.org/10.1096/FJ.201802048RRCrossRefPubMed

32.

Orava J, Nuutila P, Lidell ME et al (2011) Different metabolic responses of human brown adipose tissue to activation by cold and insulin. Cell Metab 14:272–279. https://doi.org/10.1016/j.cmet.2011.06.012CrossRefPubMed

33.

Cignarelli A, Genchi VA, Perrini S et al (2019) Insulin and insulin receptors in adipose tissue development. Int J Mol Sci 20:759. https://doi.org/10.3390/ijms20030759CrossRefPubMedPubMedCentral

34.

Saito M, Okamatsu-Ogura Y, Matsushita M et al (2009) High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 58:1526–1531. https://doi.org/10.2337/db09-0530CrossRefPubMedPubMedCentral

35.

Lee P, Greenfield JR, Ho KKY, Fulham MJ (2010) A critical appraisal of the prevalence and metabolic significance of brown adipose tissue in adult humans. Am J Physiol Endocrinol Metab 299:E601–E606. https://doi.org/10.1152/ajpendo.00298.2010CrossRefPubMed

36.

Orava J, Nuutila P, Noponen T et al (2013) Blunted metabolic responses to cold and insulin stimulation in brown adipose tissue of obese humans. Obesity (Silver Spring) 21:2279–2287. https://doi.org/10.1002/oby.20456CrossRefPubMed

37.

Pfannenberg C, Werner MK, Ripkens S et al (2010) Impact of age on the relationships of brown adipose tissue with sex and adiposity in humans. Diabetes 59:1789–1793. https://doi.org/10.2337/db10-0004CrossRefPubMedPubMedCentral

38.

Vijgen GHEJ, Bouvy ND, Teule GJJ et al (2011) Brown adipose tissue in morbidly obese subjects. PLoS ONE 6:e17247. https://doi.org/10.1371/journal.pone.0017247CrossRefPubMedPubMedCentral

39.

Villarroya F, Giralt M (2015) The beneficial effects of brown fat transplantation: further evidence of an endocrine role of brown adipose tissue. Endocrinology 156:2368–2370. https://doi.org/10.1210/en.2015-1423CrossRefPubMed

40.

Farmer SR (2006) Transcriptional control of adipocyte formation. Cell Metab 4:263–273. https://doi.org/10.1016/j.cmet.2006.07.001CrossRefPubMedPubMedCentral

41.

Linhart HG, Ishimura-Oka K, DeMayo F et al (2001) C/EBP is required for differentiation of white, but not brown, adipose tissue. Proc Natl Acad Sci U S A 98:12532–12537. https://doi.org/10.1073/pnas.211416898CrossRefPubMedPubMedCentral

42.

Kajimura S, Seale P, Kubota K et al (2009) Initiation of myoblast to brown fat switch by a PRDM16–C/EBP-β transcriptional complex. Nature 460:1154–1158. https://doi.org/10.1038/nature08262CrossRefPubMedPubMedCentral

43.

Uldry M, Yang W, St-Pierre J et al (2006) Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab 3:333–341. https://doi.org/10.1016/j.cmet.2006.04.002CrossRefPubMed

44.

Maciel MG, Beserra BTS, Oliveira FCB et al (2018) The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: a systematic review and meta-analysis. Diabetes Res Clin Pract 142:222–235. https://doi.org/10.1016/j.diabres.2018.05.034CrossRefPubMed

45.

Cypess AM, Weiner LS, Roberts-Toler C et al (2015) Activation of human brown adipose tissue by a β3-adrenergic receptor agonist. Cell Metab 21:33–38. https://doi.org/10.1016/j.cmet.2014.12.009CrossRefPubMedPubMedCentral

46.

Bajzer M, Olivieri M, Haas MK et al (2011) Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice. Diabetologia 54:3121–3131. https://doi.org/10.1007/s00125-011-2302-6CrossRefPubMedPubMedCentral

47.

Choi JK, Kim YJ, Park SY, Jung YH, Kim SC, Kwon JSL. Potent body weight loss, and therapeutic efficacy in a NASH animal model by a novel long-acting GLP-1/Glucagon/GIP tri-agonist (HM15211)—virtual meeting|EASD

48.

Kim JA, Lee S, Lee SH et al (2018) Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/Glucagon triple agonist in the neurodegenerative disease models. Diabetes 67:1107-p. https://doi.org/10.2337/db18-1107-pCrossRef

49.

Russell AP, Giacobino JP (2014) Old and new determinants in the regulation of energy expenditure. J Endocrinol Invest 25:862–866. https://doi.org/10.1007/BF03344049CrossRef

50.

Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153:586–600. https://doi.org/10.1152/ajplegacy.1948.153.3.586CrossRefPubMed

51.

D’Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994) Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263–2266. https://doi.org/10.1172/JCI117225CrossRefPubMedPubMedCentral

52.

Sandoval DA, D’Alessio DA (2015) Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 95:513–548. https://doi.org/10.1152/physrev.00013.2014CrossRefPubMed

53.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ (2003) Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114:115–121. https://doi.org/10.1016/S0167-0115(03)00111-3CrossRefPubMed

54.

Jiang G, Zhang BB (2003) Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284:E671–E678. https://doi.org/10.1152/ajpendo.00492.2002CrossRefPubMed

55.

Doi K, Kuroshima A (1982) Thermogenic response to glucagon in cold-acclimated mice. Jpn J Physiol 32:377–385. https://doi.org/10.2170/jjphysiol.32.377CrossRefPubMed

56.

Emorine LJ, Marullo S, Briend-Sutren MM et al (1989) Molecular characterization of the human β3-adrenergic receptor. Science 245:1118–1121. https://doi.org/10.1126/science.2570461CrossRefPubMed

57.

Warne T, Serrano-Vega MJ, Baker JG et al (2008) Structure of a β1-adrenergic G-protein-coupled receptor. Nature 454:486–491. https://doi.org/10.1038/nature07101CrossRefPubMedPubMedCentral

58.

Bylund DB (1988) Sub types of α2-adrenoceptors: pharmacological and molecular biological evidence converg. Trends Pharmacol Sci 9:356–361. https://doi.org/10.1016/0165-6147(88)90254-4CrossRefPubMed

59.

Krief S, Lonnqvist F, Raimbault S et al (1993) Tissue distribution of β3-adrenergic receptor mRNA in man. J Clin Invest 91:344–349. https://doi.org/10.1172/JCI116191CrossRefPubMedPubMedCentral

60.

Evans BA, Papaioannou M, Hamilton S, Summers RJ (1999) Alternative splicing generates two isoforms of the β3-adrenoceptor which are differentially expressed in mouse tissues. Br J Pharmacol 127:1525–1531. https://doi.org/10.1038/sj.bjp.0702688CrossRefPubMedPubMedCentral

61.

Fricke K, Heitland A, Maronde E (2004) Cooperative activation of lipolysis by protein kinase A and protein kinase C pathways in 3T3-L1 adipocytes. Endocrinology 145:4940–4947. https://doi.org/10.1210/en.2004-0803CrossRefPubMed

62.

Cero C, Johnson JW, O’Mara A et al (2019) 137-OR: the selective human beta 3 adrenergic receptor mirabegron potently activates lipolysis in human white adipocytes. Diabetes 68:137-or. https://doi.org/10.2337/db19-137-orCrossRef

63.

Cero C, Lea HJ, Zhu KY et al (2021) β3-Adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis. JCI Insight 6:e139160. https://doi.org/10.1172/jci.insight.139160CrossRefPubMedPubMedCentral

64.

Chernogubova E, Cannon B, Bengtsson T (2004) Norepinephrine increases glucose transport in brown adipocytes via beta3-adrenoceptors through a cAMP, PKA, and PI3-kinase-dependent pathway stimulating conventional and novel PKCs. Endocrinology 145:269–280. https://doi.org/10.1210/EN.2003-0857CrossRefPubMed

65.

Cao W, Medvedev VA, Daniel KW, Collins S (2001) β-Adrenergic activation of p38 MAP kinase in adipocytes. J Biol Chem 276:27077–27082. https://doi.org/10.1074/jbc.M101049200CrossRefPubMed

66.

Fedorenko A, Lishko VP, Kirichok Y (2012) Mechanism of fatty-acid-dependent UCP1 uncoupling in brown fat mitochondria. Cell 151:400–413. https://doi.org/10.1016/j.cell.2012.09.010CrossRefPubMedPubMedCentral

67.

Chartoumpekis VD, Habeos IG, Ziros PG et al (2011) Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol Med 17:736–740. https://doi.org/10.2119/molmed.2011.00075CrossRefPubMedPubMedCentral

68.

Fisher FF, Kleiner S, Douris N et al (2012) FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev 26:271–281. https://doi.org/10.1101/gad.177857.111CrossRefPubMedPubMedCentral

69.

Cantó C, Auwerx J (2009) PGC-1α, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol 20:98–105. https://doi.org/10.1097/MOL.0b013e328328d0a4CrossRefPubMedPubMedCentral

70.

Lin SJ, Ford E, Haigis M et al (2004) Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev 18:12–16. https://doi.org/10.1101/gad.1164804CrossRefPubMedPubMedCentral

71.

Lim S, Park J, Um JY (2019) Ginsenoside Rb1 induces beta 3 adrenergic receptor–dependent lipolysis and thermogenesis in 3T3-L1 adipocytes and db/db mice. Front Pharmacol 10:1154. https://doi.org/10.3389/fphar.2019.01154CrossRefPubMedPubMedCentral

72.

Park S, Ahn IS, Kwon DY et al (2008) Ginsenosides Rb1 and Rg1 suppress triglyceride accumulation in 3T3-L1 adipocytes and enhance β cell insulin secretion and viability in min6 cells via PKA-dependent pathways. Biosci Biotechnol Biochem 72:2815–2823. https://doi.org/10.1271/bbb.80205CrossRefPubMed

73.

Liu H, Wang J, Liu M et al (2018) Antiobesity effects of ginsenoside Rg1 on 3T3-L1 preadipocytes and high fat diet-induced obese mice mediated by AMPK. Nutrients 10:830. https://doi.org/10.3390/nu10070830CrossRefPubMedPubMedCentral

74.

Gonzalez-Hurtado E, Lee J, Choi J, Wolfgang MJ (2018) Fatty acid oxidation is required for active and quiescent brown adipose tissue maintenance and thermogenic programing. Mol Metab 7:45–56. https://doi.org/10.1016/j.molmet.2017.11.004CrossRefPubMed

75.

Zheng Z, Liu X, Zhao Q et al (2014) Regulation of UCP1 in the browning of epididymal adipose tissue by β 3-adrenergic agonist: a role for microRNAs. Int J Endocrinol 2014:530636. https://doi.org/10.1155/2014/530636CrossRefPubMedPubMedCentral

76.

Xiao C, Goldgof M, Gavrilova O, Reitman ML (2015) Anti-obesity and metabolic efficacy of the β3-adrenergic agonist, CL316243, in mice at thermoneutrality compared to 22 °C. Obesity 23:1450–1459. https://doi.org/10.1002/oby.21124CrossRefPubMed

77.

Mowers J, Uhm M, Reilly SM et al (2013) Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKε and TBK1. Elife 2:1119. https://doi.org/10.7554/ELIFE.01119CrossRef

78.

Valentine JM, Ahmadian M, Keinan O et al (2022) β3-Adrenergic receptor downregulation leads to adipocyte catecholamine resistance in obesity. J Clin Invest 132:e153357. https://doi.org/10.1172/JCI153357CrossRefPubMedPubMedCentral

79.

Dixon TM, Daniel KW, Farmer SR, Collins S (2001) CCAAT/enhancer-binding protein alpha is required for transcription of the beta 3-adrenergic receptor gene during adipogenesis. J Biol Chem 276:722–728. https://doi.org/10.1074/JBC.M008440200CrossRefPubMed

80.

Fukuda M, Williams KW, Gautron L, Elmquist JK (2011) Induction of leptin resistance by activation of cAMP-Epac signaling. Cell Metab 13:331. https://doi.org/10.1016/J.CMET.2011.01.016CrossRefPubMedPubMedCentral

81.

Genchi VA, D’oria R, Palma G et al (2021) Impaired leptin signalling in obesity: is leptin a new thermolipokine? Int J Mol Sci 22:6445. https://doi.org/10.3390/IJMS22126445CrossRefPubMedPubMedCentral

82.

Myrbetriq (mirabegron) FDA Approval History—Drugs.com. https://www.drugs.com/history/myrbetriq.html. Accessed 12 Dec 2022

83.

Finlin BS, Memetimin H, Zhu B et al (2020) The β3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans. J Clin Invest 130:2319–2331. https://doi.org/10.1172/JCI134892CrossRefPubMedPubMedCentral

84.

Columbano A, Chiellini G, Kowalik MA (2017) GC-1: a thyromimetic with multiple therapeutic applications in liver disease. Gene Expr 17:265–275. https://doi.org/10.3727/105221617X14968563796227CrossRefPubMedPubMedCentral

85.

Coppola M, Cioffi F, Moreno M et al (2016) 3,5-diiodo-l-thyronine: a possible pharmacological agent? Curr Drug Deliv 13:330–338. https://doi.org/10.2174/1567201813666151123124340CrossRefPubMed

86.

Lahesmaa M, Orava J, Schalin-Jäntti C et al (2014) Hyperthyroidism increases brown fat metabolism in humans. J Clin Endocrinol Metab 99(1):E28-35. https://doi.org/10.1210/JC.2013-2312CrossRefPubMed

87.

Ross DS, Burch HB, Cooper DS et al (2016) American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26:1343–1421. https://doi.org/10.1089/THY.2016.0229CrossRefPubMed

88.

Martínez-Sánchez N, Alvarez CV, Fernø J et al (2014) Hypothalamic effects of thyroid hormones on metabolism. Best Pract Res Clin Endocrinol Metab 28:703–712. https://doi.org/10.1016/J.BEEM.2014.04.004CrossRefPubMed

89.

López M, Varela L, Vázquez MJ et al (2010) Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 16:1001–1008. https://doi.org/10.1038/NM.2207CrossRefPubMedPubMedCentral

90.

Lundbäck V, Kulyté A, Dahlman I, Marcus C (2020) Adipose-specific inactivation of thyroid stimulating hormone receptors in mice modifies body weight, temperature and gene expression in adipocytes. Physiol Rep 8(16):e14538. https://doi.org/10.14814/PHY2.14538CrossRefPubMedPubMedCentral

91.

Ramadan W, Marsili A, Larsen PR et al (2011) Type-2 iodothyronine 5’deiodinase (D2) in skeletal muscle of C57Bl/6 mice. II. Evidence for a role of D2 in the hypermetabolism of thyroid hormone receptor alpha-deficient mice. Endocrinology 152:3093–3102. https://doi.org/10.1210/EN.2011-0139CrossRefPubMedPubMedCentral

92.

Ma Y, Shen S, Yan Y et al (2023) Adipocyte thyroid hormone β receptor-mediated hormone action fine-tunes the intracellular glucose and lipid metabolism and systemic homeostasis. Diabetes. https://doi.org/10.2337/DB22-0656CrossRefPubMed

93.

Jakobsson T, Vedin LL, Parini P (2017) Potential role of thyroid receptor β agonists in the treatment of hyperlipidemia. Drugs 77:1613–1621. https://doi.org/10.1007/S40265-017-0791-4CrossRefPubMedPubMedCentral

94.

Lee JY, Takahashi N, Yasubuchi M et al (2012) Triiodothyronine induces UCP-1 expression and mitochondrial biogenesis in human adipocytes. Am J Physiol Cell Physiol 302(2):C463–C472. https://doi.org/10.1152/AJPCELL.00010.2011CrossRefPubMed

95.

Yau WW, Singh BK, Lesmana R et al (2019) Thyroid hormone (T3) stimulates brown adipose tissue activation via mitochondrial biogenesis and MTOR-mediated mitophagy. Autophagy 15:131–150. https://doi.org/10.1080/15548627.2018.1511263CrossRefPubMed

96.

Ribeiro MO, Carvalho SD, Schultz JJ et al (2001) Thyroid hormone-sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform-specific. J Clin Invest 108:97–105. https://doi.org/10.1172/JCI12584CrossRefPubMedPubMedCentral

97.

Lin JZ, Martagón AJ, Cimini SL et al (2015) Pharmacological activation of thyroid hormone receptors elicits a functional conversion of white to brown fat. Cell Rep 13:1528–1537. https://doi.org/10.1016/J.CELREP.2015.10.022CrossRefPubMedPubMedCentral

98.

Lindsey RC, Mohan S (2017) Thyroid hormone acting via TRβ induces expression of browning genes in mouse bone marrow adipose tissue. Endocrine 56:109–120. https://doi.org/10.1007/S12020-017-1265-XCrossRefPubMedPubMedCentral

99.

Castillo M, Freitas BCG, Rosene ML et al (2010) Impaired metabolic effects of a thyroid hormone receptor beta-selective agonist in a mouse model of diet-induced obesity. Thyroid 20:545–553. https://doi.org/10.1089/THY.2009.0318CrossRefPubMedPubMedCentral

100.

Grover GJ, Egan DM, Sleph PG et al (2004) Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3′-triiodo-l-thyronine. Endocrinology 145:1656–1661. https://doi.org/10.1210/EN.2003-0973CrossRefPubMed

101.

Bryzgalova G, Effendic S, Khan A et al (2008) Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol 111:262–267. https://doi.org/10.1016/J.JSBMB.2008.06.010CrossRefPubMed

102.

Filgueira CS, Nicolov E, Hood RL et al (2016) Sustained zero-order delivery of GC-1 from a nanochannel membrane device alleviates metabolic syndrome. Int J Obes (Lond) 40:1776–1783. https://doi.org/10.1038/IJO.2016.129CrossRefPubMed

103.

Amorim BS, Ueta CB, Freitas BCG et al (2009) A TRbeta-selective agonist confers resistance to diet-induced obesity. J Endocrinol 203:291–299. https://doi.org/10.1677/JOE-08-0539CrossRefPubMedPubMedCentral

104.

Maushart CI, Loeliger R, Gashi G et al (2019) Resolution of hypothyroidism restores cold-induced thermogenesis in humans. Thyroid 29:493–501. https://doi.org/10.1089/THY.2018.0436CrossRefPubMedPubMedCentral

105.

Broeders EPM, Vijgen GHEJ, Havekes B et al (2016) Thyroid hormone activates brown adipose tissue and increases non-shivering thermogenesis—a cohort study in a group of thyroid carcinoma patients. PLoS ONE 11(1):e0145049. https://doi.org/10.1371/journal.pone.0145049CrossRefPubMedPubMedCentral

106.

Wiersinga WM, Duntas L, Fadeyev V et al (2012) 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J 1:55–71. https://doi.org/10.1159/000339444CrossRefPubMedPubMedCentral

107.

Bjerkreim BA, Hammerstad SS, Gulseth HL et al (2021) Effect of liothyronine treatment on dermal temperature and activation of brown adipose tissue in female hypothyroid patients: a randomized crossover study. Front Endocrinol (Lausanne) 12:785175. https://doi.org/10.3389/FENDO.2021.785175CrossRefPubMed

108.

Mudaliar S, Henry RR, Sanyal AJ et al (2013) Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145(3):574–82.e1. https://doi.org/10.1053/J.GASTRO.2013.05.042CrossRefPubMed

109.

Cariou B, Van Harmelen K, Duran-Sandoval D et al (2006) The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281:11039–11049. https://doi.org/10.1074/JBC.M510258200CrossRefPubMed

110.

Watanabe M, Houten SM, Mataki C et al (2006) Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484–489. https://doi.org/10.1038/NATURE04330CrossRefPubMed

111.

Abdelkarim M, Caron S, Duhem C et al (2010) The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways. J Biol Chem 285:36759–36767. https://doi.org/10.1074/JBC.M110.166231CrossRefPubMedPubMedCentral

112.

Prawitt J, Abdelkarim M, Stroeve JHM et al (2011) Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 60:1861–1871. https://doi.org/10.2337/DB11-0030CrossRefPubMedPubMedCentral

113.

Yang J, de Vries HD, Mayeuf-Louchart A et al (2023) Role of bile acid receptor FXR in development and function of brown adipose tissue. Biochim Biophys Acta Mol Cell Biol Lipids. https://doi.org/10.1016/J.BBALIP.2022.159257CrossRefPubMed

114.

Comeglio P, Cellai I, Mello T et al (2018) INT-767 prevents NASH and promotes visceral fat brown adipogenesis and mitochondrial function. J Endocrinol 238:107–127. https://doi.org/10.1530/JOE-17-0557CrossRefPubMed

115.

Carino A, Cipriani S, Marchianò S et al (2017) BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. Sci Rep. https://doi.org/10.1038/SREP42801CrossRefPubMedPubMedCentral

116.

Kim HL, Jung Y, Park J et al (2017) Farnesol has an anti-obesity effect in high-fat diet-induced obese mice and induces the development of beige adipocytes in human adipose tissue derived-mesenchymal stem cells. Front Pharmacol 8:654. https://doi.org/10.3389/FPHAR.2017.00654CrossRefPubMedPubMedCentral

117.

Cho SY, Lim S, Ahn KS et al (2021) Farnesol induces mitochondrial/peroxisomal biogenesis and thermogenesis by enhancing the AMPK signaling pathway in vivo and in vitro. Pharmacol Res 163:105312. https://doi.org/10.1016/J.PHRS.2020.105312CrossRefPubMed

118.

Fang S, Suh JM, Reilly SM et al (2015) Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 21:159–165. https://doi.org/10.1038/NM.3760CrossRefPubMedPubMedCentral

119.

Watanabe M, Horai Y, Houten SM et al (2011) Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem 286:26913–26920. https://doi.org/10.1074/JBC.M111.248203CrossRefPubMedPubMedCentral

120.

Deckmyn B, Domenger D, Blondel C et al (2022) Farnesoid X receptor activation in brain alters brown adipose tissue function via the sympathetic system. Front Mol Neurosci 14:808603. https://doi.org/10.3389/FNMOL.2021.808603CrossRefPubMedPubMedCentral

121.

Teodoro JS, Zouhar P, Flachs P et al (2014) Enhancement of brown fat thermogenesis using chenodeoxycholic acid in mice. Int J Obes (Lond) 38:1027–1034. https://doi.org/10.1038/IJO.2013.230CrossRefPubMed

122.

Goto T, Il KY, Funakoshi K et al (2011) Farnesol, an isoprenoid, improves metabolic abnormalities in mice via both PPARα-dependent and -independent pathways. Am J Physiol Endocrinol Metab 301(5):E1022–E1032. https://doi.org/10.1152/AJPENDO.00061.2011CrossRefPubMed

123.

Zhang H, Dong M, Liu X (2021) Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat. Exp Ther Med 22(3):991. https://doi.org/10.3892/ETM.2021.10423CrossRefPubMedPubMedCentral

124.

De Giorgi S, Campos V, Egli L et al (2015) Long-term effects of Roux-en-Y gastric bypass on postprandial plasma lipid and bile acids kinetics in female non diabetic subjects: a cross-sectional pilot study. Clin Nutr 34:911–917. https://doi.org/10.1016/J.CLNU.2014.09.018CrossRefPubMed

125.

Kohli R, Bradley D, Setchell KD et al (2013) Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab. https://doi.org/10.1210/JC.2012-3736CrossRefPubMedPubMedCentral

126.

Broeders EPM, Nascimento EBM, Havekes B et al (2015) The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. Cell Metab 22:418–426. https://doi.org/10.1016/J.CMET.2015.07.002CrossRefPubMed

127.

Alawad AS, Levy C (2016) FXR agonists: from bench to bedside, a guide for clinicians. Dig Dis Sci 61:3395–3404. https://doi.org/10.1007/S10620-016-4334-8CrossRefPubMed

128.

Muscogiuri G, Cignarelli A, Giorgino F et al (2014) GLP-1: benefits beyond pancreas. J Endocrinol Invest 37:1143–1153. https://doi.org/10.1007/S40618-014-0137-Y/TABLES/1CrossRefPubMed

129.

Baggio LL, Drucker DJ (2014) Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest 124:4223–4226. https://doi.org/10.1172/JCI78371CrossRefPubMedPubMedCentral

130.

Flint A, Raben A, Ersbøll AK et al (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes 25:781–792. https://doi.org/10.1038/sj.ijo.0801627CrossRef

131.

Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131–2157. https://doi.org/10.1053/j.gastro.2007.03.054CrossRefPubMed

132.

Vilsbøll T, Krarup T, Sonne J et al (2003) Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88:2706–2713. https://doi.org/10.1210/jc.2002-021873CrossRefPubMed

133.

Rotella CM, Pala L, Mannucci E (2005) Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J Endocrinol Invest 28:746–758. https://doi.org/10.1007/BF03347560CrossRefPubMed

134.

Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17:819–837. https://doi.org/10.1016/j.cmet.2013.04.008CrossRefPubMed

135.

Richards P, Parker HE, Adriaenssens AE et al (2014) Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63:1224–1233. https://doi.org/10.2337/db13-1440CrossRefPubMed

136.

Müller TD, Finan B, Bloom SR et al (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72–130. https://doi.org/10.1016/j.molmet.2019.09.010CrossRefPubMedPubMedCentral

137.

Bertin E, Arner P, Bolinder J, Hagström-Toft E (2001) Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab 86:1229–1234. https://doi.org/10.1210/jcem.86.3.7330CrossRefPubMed

138.

Mérida E, Delgado E, Molina LM et al (1993) Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab 77:1654–1657. https://doi.org/10.1210/jcem.77.6.8263154CrossRefPubMed

139.

Campbell JE, Beaudry JL, Svendsen B et al (2022) GIPR is predominantly localized to nonadipocyte cell types within white adipose tissue. Diabetes 71:1115–1127. https://doi.org/10.2337/DB21-1166CrossRefPubMedPubMedCentral

140.

Emont MP, Jacobs C, Essene AL et al (2022) A single-cell atlas of human and mouse white adipose tissue. Nature 603:926–933. https://doi.org/10.1038/S41586-022-04518-2CrossRefPubMedPubMedCentral

141.

Ørskov C, Wettergren A, Holst JJ (1996) Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 31:665–670. https://doi.org/10.3109/00365529609009147CrossRefPubMed

142.

Russell-Jones D (2009) Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 297:137–140. https://doi.org/10.1016/J.MCE.2008.11.018CrossRefPubMed

143.

Wang X, Chen J, Rong C et al (2018) GLP-1RA promotes brown adipogenesis of C3H10T1/2 mesenchymal stem cells via the PI3K-AKT-mTOR signaling pathway. Biochem Biophys Res Commun 506:976–982. https://doi.org/10.1016/j.bbrc.2018.10.197CrossRefPubMed

144.

Xu F, Lin B, Zheng X et al (2016) GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1. Diabetologia 59:1059–1069. https://doi.org/10.1007/S00125-016-3896-5/FIGURES/6CrossRefPubMed

145.

Heppner KM, Marks S, Holland J et al (2015) Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice. Diabetologia 58:2124–2132. https://doi.org/10.1007/s00125-015-3651-3CrossRefPubMedPubMedCentral

146.

Morrison SF, Madden CJ, Tupone D (2014) Central neural regulation of brown adipose tissue thermogenesis and energy expenditure. Cell Metab 19:741–756. https://doi.org/10.1016/J.CMET.2014.02.007CrossRefPubMedPubMedCentral

147.

Kanoski SE, Hayes MR, Skibicka KP (2016) GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol 310:R885–R895. https://doi.org/10.1152/ajpregu.00520.2015CrossRefPubMedPubMedCentral

148.

Lee SJ, Sanchez-Watts G, Krieger JP et al (2018) Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity. Mol Metab 11:33–46. https://doi.org/10.1016/j.molmet.2018.03.008CrossRefPubMedPubMedCentral

149.

Kooijman S, Wang Y, Parlevliet ET et al (2015) Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice. Diabetologia 58:2637–2646. https://doi.org/10.1007/s00125-015-3727-0CrossRefPubMedPubMedCentral

150.

Nogueiras R, Perez-Tilve D, Veyrat-Durebex C et al (2009) Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 29:5916–5925. https://doi.org/10.1523/JNEUROSCI.5977-08.2009CrossRefPubMedPubMedCentral

151.

Sisley S, Gutierrez-Aguilar R, Scott M et al (2014) Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J Clin Invest 124:2456–2463. https://doi.org/10.1172/JCI72434CrossRefPubMedPubMedCentral

152.

Nonogaki K, Hazama M, Satoh N (2014) Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKA ^y mice. Biomed Res Int 2014:1–8. https://doi.org/10.1155/2014/751930CrossRef

153.

Zhou J, Poudel A, Chandramani-Shivalingappa P et al (2019) Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway. Endocrine 64:271–283. https://doi.org/10.1007/s12020-018-1826-7CrossRefPubMed

154.

López M, Diéguez C, Nogueiras R (2014) Hypothalamic GLP-1: the control of BAT thermogenesis and browning of white fat. Adipocyte 4:141–145. https://doi.org/10.4161/21623945.2014.983752CrossRef

155.

Zhou JY, Poudel A, Welchko R et al (2019) Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways. Eur J Pharmacol 861:172594. https://doi.org/10.1016/j.ejphar.2019.172594CrossRefPubMed

156.

Chau MDL, Gao J, Yang Q et al (2010) Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1α pathway. Proc Natl Acad Sci U S A 107:12553–12558. https://doi.org/10.1073/pnas.1006962107CrossRefPubMedPubMedCentral

157.

Yamaguchi S, Franczyk MP, Chondronikola M et al (2019) Adipose tissue NAD+ biosynthesis is required for regulating adaptive thermogenesis and whole-body energy homeostasis in mice. Proc Natl Acad Sci U S A 116:23822–23828. https://doi.org/10.1073/pnas.1909917116CrossRefPubMedPubMedCentral

158.

Xu F, Zheng X, Lin B et al (2016) Diet-induced obesity and insulin resistance are associated with brown fat degeneration in SIRT1-deficient mice. Obesity 24:634–642. https://doi.org/10.1002/oby.21393CrossRefPubMed

159.

Baskaran P, Krishnan V, Fettel K et al (2017) TRPV1 activation counters diet-induced obesity through sirtuin-1 activation and PRDM-16 deacetylation in brown adipose tissue. Int J Obes 41:739–749. https://doi.org/10.1038/ijo.2017.16CrossRef

160.

Zhu E, Yang Y, Zhang J et al (2016) Liraglutide suppresses obesity and induces brown fat-like phenotype via Soluble Guanylyl Cyclase mediated pathway in vivo and in vitro. Oncotarget 7:81077–81089. https://doi.org/10.18632/oncotarget.13189CrossRefPubMedPubMedCentral

161.

Hoffmann LS, Etzrodt J, Willkomm L et al (2015) Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue. Nat Commun 6:7235. https://doi.org/10.1038/ncomms8235CrossRefPubMed

162.

Hoffmann LS, Larson CJ, Pfeifer A (2015) cGMP and brown adipose tissue. Handb Exp Pharmacol 233:283–299. https://doi.org/10.1007/164_2015_3CrossRef

163.

Decara J, Rivera P, Arrabal S et al (2018) Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats. Acta Physiol 222:e13008. https://doi.org/10.1111/apha.13008CrossRef

164.

Wan Y, Bao X, Huang J et al (2017) Novel GLP-1 analog supaglutide reduces HFD-induced obesity associated with increased Ucp-1 in white adipose tissue in mice. Front Physiol 8:294. https://doi.org/10.3389/FPHYS.2017.00294CrossRefPubMedPubMedCentral

165.

Martins FF, Marinho TS, Cardoso LEM et al (2022) Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice. Cell Biochem Funct 40(8):903–913. https://doi.org/10.1002/CBF.3751CrossRefPubMed

166.

Harder H, Nielsen L, Thi TDT, Astrup A (2004) The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 27:1915–1921. https://doi.org/10.2337/diacare.27.8.1915CrossRefPubMed

167.

Bradley DP, Kulstad R, Racine N et al (2012) Alterations in energy balance following exenatide administration. Appl Physiol Nutr Metab 37:893–899. https://doi.org/10.1139/H2012-068CrossRefPubMedPubMedCentral

168.

Horowitz M, Flint A, Jones KL et al (2012) Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract 97:258–266. https://doi.org/10.1016/j.diabres.2012.02.016CrossRefPubMed

169.

Janssen LGM, Nahon KJ, Bracké KFM et al (2020) Twelve weeks of exenatide treatment increases [18F] fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males. Metabolism 106:154167. https://doi.org/10.1016/j.metabol.2020.154167CrossRefPubMed

170.

Saxenda (liraglutide) FDA approval history—drugs.com. https://www.drugs.com/history/saxenda.html. Accessed 11 Dec 2022

171.

Victoza (liraglutide) FDA Approval history—drugs.com. https://www.drugs.com/history/victoza.html. Accessed 11 Dec 2022

172.

O’Neil PM, Birkenfeld AL, McGowan B et al (2018) Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 392:637–649. https://doi.org/10.1016/S0140-6736(18)31773-2CrossRefPubMed

173.

Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989–1002. https://doi.org/10.1056/NEJMOA2032183/SUPPL_FILE/NEJMOA2032183_DATA-SHARING.PDFCrossRefPubMed

174.

Brown adipose tissue activity in response to semaglutide administered to obese subjects. - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05419726. Accessed 11 Dec 2022

175.

Theodorakis MJ, Carlson O, Michopoulos S et al (2006) Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab 290(3):E550–E559. https://doi.org/10.1152/ajpendo.00326.2004CrossRefPubMed

176.

Alssema M, Rijkelijkhuizen JM, Holst JJ et al (2013) Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. Eur J Endocrinol 169:421–430. https://doi.org/10.1530/EJE-13-0487CrossRefPubMed

177.

Irwin N, Francis JME, Flatt PR (2011) Alterations of glucose-dependent insulinotropic polypeptide (GIP) during cold acclimation. Regul Pept 167:91–96. https://doi.org/10.1016/j.regpep.2010.12.001CrossRefPubMed

178.

Beaudry JL, Drucker DJ (2020) Proglucagon-derived peptides, glucose-dependent insulinotropic polypeptide, and dipeptidyl peptidase-4-mechanisms of action in adipose tissue. Endocrinology 161(1):bqz029. https://doi.org/10.1210/endocr/bqz029CrossRefPubMed

179.

Yip RGC, Boylan MO, Kieffer TJ, Wolfe MM (1998) Functional GIP receptors are present on adipocytes. Endocrinology 139:4004–4007. https://doi.org/10.1210/endo.139.9.6288CrossRefPubMed

180.

Weaver RE, Donnelly D, Wabitsch M et al (2008) Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model. Int J Obes 32:1705–1711. https://doi.org/10.1038/ijo.2008.148CrossRef

181.

Ceperuelo-Mallafré V, Duran X, Pachón G et al (2014) Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. J Clin Endocrinol Metab 99(5):E908–E919. https://doi.org/10.1210/jc.2013-3350CrossRefPubMed

182.

Natalicchio A, Biondi G, Marrano N et al (2016) Long-term exposure of pancreatic β-Cells to palmitate results in SREBP-1C-dependent decreases in GLP-1 receptor signaling via CREB and AKT and insulin secretory response. Endocrinology 157:2243–2258. https://doi.org/10.1210/EN.2015-2003CrossRefPubMed

183.

Mantelmacher FD, Zvibel I, Cohen K et al (2019) GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9. Nat Metab 1:58–69. https://doi.org/10.1038/s42255-018-0001-zCrossRefPubMed

184.

Chen X, He X, Guo Y et al (2021) Glucose-dependent insulinotropic polypeptide modifies adipose plasticity and promotes beige adipogenesis of human omental adipose-derived stem cells. FASEB J 35:e21534. https://doi.org/10.1096/FJ.201903253RCrossRefPubMed

185.

NamKoong C, Kim MS, Jang BT et al (2017) Central administration of GLP-1 and GIP decreases feeding in mice. Biochem Biophys Res Commun 490:247–252. https://doi.org/10.1016/j.bbrc.2017.06.031CrossRefPubMed

186.

Fenselau H, Campbell JN, Verstegen AMJ et al (2017) A rapidly acting glutamatergic ARC→PVH satiety circuit postsynaptically regulated by α-MSH. Nat Neurosci 20:42–51. https://doi.org/10.1038/nn.4442CrossRefPubMed

187.

Péterfi Z, Farkas I, Denis RGP et al (2018) Endocannabinoid and nitric oxide systems of the hypothalamic paraventricular nucleus mediate effects of NPY on energy expenditure. Mol Metab 18:120–133. https://doi.org/10.1016/j.molmet.2018.08.007CrossRefPubMedPubMedCentral

188.

Finan B, Ma T, Ottaway N et al (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5(209):209–151. https://doi.org/10.1126/scitranslmed.3007218CrossRef

189.

Coskun T, Sloop KW, Loghin C et al (2018) LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 18:3–14. https://doi.org/10.1016/j.molmet.2018.09.009CrossRefPubMedPubMedCentral

190.

Samms RJ, Christe ME, Collins KAL, et al. (2021) GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest 131(12): e146353. https://doi.org/10.1172/JCI146353

191.

Samms RJ, Zhang GF, He W, et al (2022) Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue. Mol Metab 64:101550. https://doi.org/10.1016/J.MOLMET.2022.101550

192.

Frias JP, Bastyr EJ, Vignati L et al (2017) The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab 26:343-352.e2. https://doi.org/10.1016/J.CMET.2017.07.011CrossRefPubMed

193.

Frías JP, Davies MJ, Rosenstock J, et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385:503–515. https://www.nejm.org/doi/https://doi.org/10.1056/NEJMoa2107519

194.

Cusi K, Isaacs S, Barb D et al (2022) American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 28:528–562. https://doi.org/10.1016/J.EPRAC.2022.03.010CrossRefPubMed

195.

Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387:205–216. https://doi.org/10.1056/NEJMOA2206038CrossRefPubMed

196.

Ludvik B, Giorgino F, Jódar E et al (2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 398:583–598. https://doi.org/10.1016/S0140-6736(21)01443-4CrossRefPubMed

197.

Chang SH, Stoll CRT, Song J et al (2014) The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg 149:275–287. https://doi.org/10.1001/JAMASURG.2013.3654CrossRefPubMedPubMedCentral

198.

Willard FS, Douros JD, Gabe MBN, et al (2020) Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5(17):e140532. https://doi.org/10.1172/JCI.INSIGHT.140532

199.

A study to measure food and calorie consumption in very overweight participants using Tirzepatide - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04081337. Accessed 12 Dec 2022

200.

Pirro V, Roth KD, Lin Y et al (2022) Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with type 2 diabetes. J Clin Endocrinol Metab 107:363–378. https://doi.org/10.1210/CLINEM/DGAB722CrossRefPubMed

201.

Woods SC, Lutz TA, Geary N, Langhans W (2006) Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc B 361:1219–1235. https://doi.org/10.1098/rstb.2006.1858CrossRef

202.

Galsgaard KD, Pedersen J, Knop FK et al (2019) Glucagon receptor signaling and lipid metabolism. Front Physiol 10:413. https://doi.org/10.3389/fphys.2019.00413CrossRefPubMedPubMedCentral

203.

Jones BJ, Tan T, Bloom S (2012) Minireview: glucagon in stress and energy homeostasis. Endocrinology 153:1049–1054. https://doi.org/10.1210/en.2011-1979CrossRefPubMedPubMedCentral

204.

Campbell JE, Drucker DJ (2015) Islet α cells and glucagon-critical regulators of energy homeostasis. Nat Rev Endocrinol 11:329–338. https://doi.org/10.1038/nrendo.2015.51CrossRefPubMed

205.

Kleinert M, Sachs S, Habegger KM et al (2019) Glucagon regulation of energy expenditure. Int J Mol Sci 20(21):5407. https://doi.org/10.3390/ijms20215407CrossRefPubMedPubMedCentral

206.

Beaudry JL, Kaur KD, Varin EM et al (2019) The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice. Mol Metab 22:37–48. https://doi.org/10.1016/j.molmet.2019.01.011CrossRefPubMedPubMedCentral

207.

Richter WO, Robl H, Schwandt P (1989) Human glucagon and vasoactive intestinal polypeptide (VIP) stimulate free fatty acid release from human adipose tissue in vitro. Peptides (NY) 10:333–335. https://doi.org/10.1016/0196-9781(89)90039-9CrossRef

208.

Perea A, Clemente F, Martinell J et al (1995) Physiological effect of glucagon in human isolated adipocytes. Horm Metab Res 27:372–375. https://doi.org/10.1055/s-2007-979981CrossRefPubMed

209.

Davidson IWF, Salter JM, Best CH (1957) Calorigenic action of glucagon. Nature 180(4595):1124. https://doi.org/10.1038/1801124a0CrossRefPubMed

210.

Salter JM, Davidson IW, Best CW (1957) The pathologic effects of large amounts of glucagon. Diabetes 6(3):248–252. https://doi.org/10.2337/diab.6.3.248CrossRefPubMed

211.

Chan EK, Mackey MA, Snover DC et al (1984) Suppression of weight gain by glucagon in obese Zucker rats. Exp Mol Pathol 40:320–327. https://doi.org/10.1016/0014-4800(84)90049-2CrossRefPubMed

212.

Heim T, Hull D (1966) The effect of propranalol on the calorigenic response in brown adipose tissue of new-born rabbits to catecholamines, glucagon, corticotrophin and cold exposure. J Physiol 187:271–283. https://doi.org/10.1113/jphysiol.1966.sp008088CrossRefPubMedPubMedCentral

213.

Salem V, Izzi-Engbeaya C, Coello C et al (2016) Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes Obes Metab 18:72–81. https://doi.org/10.1111/dom.12585CrossRefPubMed

214.

Kedia, (2011) Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. Diabetes Metab Syndr Obes 4:337. https://doi.org/10.2147/dmso.s20633CrossRefPubMed

215.

Day JW, Ottaway N, Patterson JT et al (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:749–757. https://doi.org/10.1038/nchembio.209CrossRefPubMed

216.

Perea A, Viñambres C, Clemente F et al (1997) GLP-1 (7–36) amide: effects on glucose transport and metabolism in rat adipose tissue. Horm Metab Res 29:417–421. https://doi.org/10.1055/s-2007-979068CrossRefPubMed

217.

Pocai A, Carrington PE, Adams JR et al (2009) Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58:2258–2266. https://doi.org/10.2337/db09-0278CrossRefPubMedPubMedCentral

218.

Henderson SJ, Konkar A, Hornigold DC et al (2016) Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab 18:1176–1190. https://doi.org/10.1111/dom.12735CrossRefPubMedPubMedCentral

219.

Oldham S, Church CD, Will S, et al (2018) Evaluating the sub-chronic effects of MEDI0382, a GLP-1/glucagon receptor dual agonist, on weight loss in male ob/ob mice. Diabetes 67:1890P. https://doi.org/10.2337/db18-1890-p

220.

Tan TM, Field BCT, McCullough KA et al (2013) Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes 62:1131. https://doi.org/10.2337/DB12-0797CrossRefPubMedPubMedCentral

221.

Wynne K, Park AJ, Small CJ, et al (2006) Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes. 2006 30:1729–1736. https://doi.org/10.1038/sj.ijo.0803344

222.

Nahra R, Wang T, Gadde KM et al (2021) Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study. Diabetes Care 44:1433. https://doi.org/10.2337/DC20-2151CrossRefPubMedPubMedCentral

223.

Ji L, Gao L, Jiang H, et al (2022) Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine 54:101691. https://doi.org/10.1016/j.eclinm.2022.101691

224.

A study of IBI362 evaluating weight loss in obese and overweight chinese subjects - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04904913?term=IBI362&draw=2&rank=7. Accessed 13 Dec 2022

225.

Jall S, Sachs S, Clemmensen C et al (2017) Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol Metab 6:440–446. https://doi.org/10.1016/j.molmet.2017.02.002CrossRefPubMedPubMedCentral

226.

Finan B, Yang B, Ottaway N et al (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21:27–36. https://doi.org/10.1038/nm.3761CrossRefPubMed

227.

Coskun T, Urva S, Roell WC et al (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab 34:1234-1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013CrossRefPubMed

228.

Lee JS, Lee SM, Kim JK, et al (2020) 1926-P: Potent weight loss mechanism of a novel long-acting glucagon analog, HM15136, in animal models of obesity. Diabetes 69 (Supplement_1):1926-P https://doi.org/10.2337/DB20-1926-P

229.

Study to evaluate efficacy, safety and tolerability of HM15211 in subjects - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04505436. Accessed 11 Dec 2022

230.

Urva S, Coskun T, Loh MT et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet 400:1869–1881. https://doi.org/10.1016/s0140-6736(22)02033-5CrossRef

Title: Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?
Authors: V. A. Genchi
G. Palma
G. P. Sorice
R. D’Oria
C. Caccioppoli
N. Marrano
G. Biondi
I. Caruso
A. Cignarelli
A. Natalicchio
L. Laviola
F. Giorgino
S. Perrini
Publication date: 28-06-2023
Publisher: Springer International Publishing
Keywords: Obesity
Obesity
Tirzepatide
Published in: Journal of Endocrinological Investigation / Issue 11/2023
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-023-02125-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Purpose

Please log in to get access to this content

Other articles of this Issue 11/2023

Thyroid function, sensitivity to thyroid hormones, and metabolic syndrome in euthyroid children and adolescents with Down syndrome

The phenotype of Graves’ orbitopathy is associated with thyrotropin receptor antibody levels

Study of the link between hemotopoietic and skeletal systems in patients attending a referral center for osteoporosis

Multiple beneficial effects of 1-year nutritional–behavioral intervention on anthropometric and metabolic parameters in overweight and obese boys

Androgen insensitivity syndrome: a review

Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage